Dynamic Cloud Network Control under Reconfiguration Delay and Cost

Network virtualization and programmability allow operators to deploy a wide range of services over a common physical infrastructure and elastically allocate cloud and network resources according to changing requirements. While the elastic reconfiguration of virtual resources enables dynamically scaling capacity in order to support service demands with minimal operational cost, reconfiguration operations make resources unavailable during a given time period and may incur additional cost. In this paper, we address the dynamic cloud network control problem under non-negligible reconfiguration delay and cost. We show that while the capacity region remains unchanged regardless of the reconfiguration delay/cost values, a reconfiguration-agnostic policy may fail to guarantee throughput-optimality and minimum cost under nonzero reconfiguration delay/cost. We then present an adaptive dynamic cloud network control policy that allows network nodes to make local flow scheduling and resource allocation decisions while controlling the frequency of reconfiguration in order to support any input rate in the capacity region and achieve arbitrarily close to minimum cost for any finite reconfiguration delay/cost values.Comment: 15 pages, 7 figure

Regular treatment with formoterol for chronic asthma: serious adverse events

Epidemiological evidence has suggested a link between beta(2)-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe.ObjectivesThe aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular formoterol versus placebo or regular short-acting beta2-agonists.Search methodsWe identified trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trial registers for unpublished trial data and Food and Drug Administration (FDA) submissions in relation to formoterol. The date of the most recent search was January 2012.Selection criteriaWe included controlled, parallel design clinical trials on patients of any age and severity of asthma if they randomised patients to treatment with regular formoterol and were of at least 12 weeks' duration. Concomitant use of inhaled corticosteroids was allowed, as long as this was not part of the randomised treatment regimen.Data collection and analysisTwo authors independently selected trials for inclusion in the review. One author extracted outcome data and the second author checked them. We sought unpublished data on mortality and serious adverse events.Main resultsThe review includes 22 studies (8032 participants) comparing regular formoterol to placebo and salbutamol. Non-fatal serious adverse event data could be obtained for all participants from published studies comparing formoterol and placebo but only 80% of those comparing formoterol with salbutamol or terbutaline.Three deaths occurred on regular formoterol and none on placebo; this difference was not statistically significant. It was not possible to assess disease-specific mortality in view of the small number of deaths. Non-fatal serious adverse events were significantly increased when regular formoterol was compared with placebo (Peto odds ratio (OR) 1.57; 95% CI 1.06 to 2.31). One extra serious adverse event occurred over 16 weeks for every 149 people treated with regular formoterol (95% CI 66 to 1407 people). The increase was larger in children than in adults, but the impact of age was not statistically significant. Data submitted to the FDA indicate that the increase in asthma-related serious adverse events remained significant in patients taking regular formoterol who were also on inhaled corticosteroids.No significant increase in fatal or non-fatal serious adverse events was found when regular formoterol was compared with regular salbutamol or terbutaline.Authors' conclusionsIn comparison with placebo, we have found an increased risk of serious adverse events with regular formoterol, and this does not appear to be abolished in patients taking inhaled corticosteroids. The effect on serious adverse events of regular formoterol in children was greater than the effect in adults, but the difference between age groups was not significant.Data on all-cause serious adverse events should be more fully reported in journal articles, and not combined with all severities of adverse events or limited to those events that are thought by the investigator to be drug-related

Flexible QoS Support in DVB-RCS2

Postprin

CSMA Local Area Networking under Dynamic Altruism

In this paper, we consider medium access control of local area networks (LANs) under limited-information conditions as befits a distributed system. Rather than assuming "by rule" conformance to a protocol designed to regulate packet-flow rates (e.g., CSMA windowing), we begin with a non-cooperative game framework and build a dynamic altruism term into the net utility. The effects of altruism are analyzed at Nash equilibrium for both the ALOHA and CSMA frameworks in the quasistationary (fictitious play) regime. We consider either power or throughput based costs of networking, and the cases of identical or heterogeneous (independent) users/players. In a numerical study we consider diverse players, and we see that the effects of altruism for similar players can be beneficial in the presence of significant congestion, but excessive altruism may lead to underuse of the channel when demand is low

Hydraulic simulations to evaluate and predict design and operation of the Chashma Right Bank Canal

Irrigation systems / Irrigation canals / Flow control / Velocity / Canal regulation techniques / Hydraulics / Simulation models / Design / Operations / Crop-based irrigation / Distributary canals / Water delivery / Policy / Protective irrigation / Water allocation / Water requirements / Sedimentation / Water distribution / Equity / Water conveyance / Pakistan / Chashma Right Bank Canal

An Energy and Performance Exploration of Network-on-Chip Architectures

In this paper, we explore the designs of a circuit-switched router, a wormhole router, a quality-of-service (QoS) supporting virtual channel router and a speculative virtual channel router and accurately evaluate the energy-performance tradeoffs they offer. Power results from the designs placed and routed in a 90-nm CMOS process show that all the architectures dissipate significant idle state power. The additional energy required to route a packet through the router is then shown to be dominated by the data path. This leads to the key result that, if this trend continues, the use of more elaborate control can be justified and will not be immediately limited by the energy budget. A performance analysis also shows that dynamic resource allocation leads to the lowest network latencies, while static allocation may be used to meet QoS goals. Combining the power and performance figures then allows an energy-latency product to be calculated to judge the efficiency of each of the networks. The speculative virtual channel router was shown to have a very similar efficiency to the wormhole router, while providing a better performance, supporting its use for general purpose designs. Finally, area metrics are also presented to allow a comparison of implementation costs